A preclinical study of ibrutinib provides compelling evidence that myeloid leukemias with mutated G-CSFR have abnormal activation of Btk.
Tumor microenvironments can induce T-cell senescence and exhaustion; Yangqiu Li et al highlight ways to reverse these states and improve immunotherapeutic efficacy.
Strong efficacy and safety outcomes with this agent, which targets the molecular driver of an AML subset, have led to its approval in IDH1-mutated R/R disease.
A Washington University School of Medicine team’s findings might inform future research into inhibitors of angiogenesis and PD-1 in head and neck cancer.
A team of Texas-based oncologists says their preclinical study results “demonstrate that IGF-1R and FOXC1 seem to positively regulate each other.”
Oncologist Dr. Vivek Subbiah and computer scientist Dr. Jason Roszik, both from MD Anderson, discuss optimizing “omics” databases to inform cancer patient care.
FDA, CMS, and Department of Veterans Affairs experts will be included. Dr. Robin Zon, a past chair of ASCO’s Government Relations Committee, said it is “critical” that the FDA work with providers and patients.
“Tumor cell–intrinsic factors shape the tumor immune microenvironment and influence the outcome of immunotherapy,” the lead study author concluded.
TURBT with fluorescent light source using oral 5-ALA is well tolerated in non–muscle-invasive bladder cancer.
Novel Targeted Agents for Lung Cancer: M7824, a Bifunctional Protein Targeting PD-L1 and TGB-β Receptor II
In a phase I trial, this first-in-class novel drug yielded a 71% response rate in very high expressers of PD-L1 treated at 1,200 mg every 2 weeks.